Novartis and Yuhan disputing on trademark Famvics.

Published: 2005-07-05 06:55:00

Updated: 2005-07-05 06:55:00

Novartis appealed to the Korea Patent Office on July 1 against the trade market application of Famvics (appl. no. 40-2004-0019914) filed by Yuhan who intended to use Famvics (famciclovir) for the treatment of shingles (Herpes Zoster), which was already in marketplace from Feb. this year.

Nov...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK